|Awarded On||February 16, 2022|
|Title||NOVEL METABOLOMICS AND RADIOMICS FOR PREDICTING HCC RISK|
|Award Mechanism||Individual Investigator Research Awards for Prevention and Early Detection|
|Institution/Organization||Baylor College of Medicine|
|Principal Investigator/Program Director||Hashem El-Serag|
|Cancer Sites||Gallbladder, Liver and Intrahepatic Bile Duct|
*Pending contract negotiation
Texas has the highest rates of liver cancer, also known as hepatocellular carcinoma (HCC) in the nation. Most cases of HCC arise among patients with chronic liver disease, especially cirrhosis of the liver. Fatty liver disease related to metabolic dysfunction (e.g., diabetes, obesity), also called MAFLD, has become the most common chronic liver disease in the world. Our goal is to reduce death and suffering from HCC. However, except for a small proportion of patients who are diagnosed at an early stage, a cure is not possible. Therefore, prevention of HCC is very important.
Our proposed research study investigates risk factors and novel biomarkers that can be reliably used to identify sub...